Gustavo Delaluz, MD
Pulmonary Disease · Manasquan, NJNPI 1255333043
Payments from drug & device makers
Across 586 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- GSK$2K
- Sanofi$673
- Philips North America LLC$588
- Mylan Specialty L.p.$410
- Actelion Pharmaceuticals US, Inc.$377
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$3,00024%
- Travel & lodging$560%
- Food & beverage$9,15472%
- Education$5204%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 132 | $6,103 |
| GSK | 150 | $1,880 |
| Sanofi | 40 | $673 |
| Philips North America LLC | 64 | $588 |
| Mylan Specialty L.p. | 26 | $410 |
| Actelion Pharmaceuticals US, Inc. | 18 | $377 |
| Harmony Biosciences LLC | 17 | $364 |
| Boehringer Ingelheim | 29 | $346 |
| Regeneron Healthcare Solutions, Inc. | 19 | $305 |
| Jazz Pharmaceuticals Inc. | 21 | $302 |
| Sanofi-aventis U.S. LLC | 3 | $259 |
| Inspire Medical Systems, Inc. | 4 | $194 |
| Amgen | 13 | $191 |
| Viatris Specialty LLC | 13 | $151 |
| Avadel CNS Pharmaceuticals, LLC | 5 | $86 |
| Insmed, Inc. | 5 | $83 |
| Sunovion Pharmaceuticals Inc. | 7 | $78 |
| Grifols USA, LLC | 4 | $69 |
| United Therapeutics Corporation | 4 | $66 |
| Novartis | 3 | $49 |
| Lilly USA, LLC | 2 | $45 |
| Baxter Healthcare | 1 | $19 |
| Merck | 1 | $18 |
| Bayer | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Verona Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,730 in reported general payments places this provider in the 85th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 489 | $475,803 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 238 | $226,241 |
| Fasenra PenBenralizumab | 36 | $209,277 |
| Dupixent PenDupilumab | 52 | $188,958 |
| Breo ElliptaFluticasone/Vilanterol | 219 | $121,685 |
| FasenraBenralizumab | 15 | $88,446 |
| TezspireTezepelumab-Ekko | 15 | $66,350 |
| Spiriva RespimatTiotropium Bromide | 87 | $65,847 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 99 | $64,729 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 26 | $59,660 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 54 | $49,227 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 476 | $20,994 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $18,254 |
| EliquisApixaban | 13 | $15,283 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 76 | $14,772 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,880 | $680,532851 claims |
| AstraZenecaBreztri Aerosphere, Fasenra, Tezspire, Symbicort, Airsupra | $6,103 | $421,714345 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $346 | $124,050156 claims |
| Grifols USA, LLCGamunex-C | $69 | $59,66026 claims |
| MerckDulera, Asmanex | $18 | $14,77629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Manasquan
- Jeffrey MiskoffManasquan$228K
- Paul FriedmanManasquan$58K
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.